Platelet Rich Plasma for Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia Clinical Trial

Official title:

Assessment of the Safety and Efficacy of Intralesional Platelet Rich Plasma in Reducing Scalp Symptoms and Promoting Hair Growth in Frontal Fibrosing Alopecia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03335228
• Other study ID #: DERM-2020-28608
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 1, 2025
• Est. completion date: September 2026

Study information

• Verified date: April 2024
• Source: University of Minnesota
• Contact: Angela Wipf, BS
• Phone: (612) 624-5721
• Email: derm[@]umn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the efficacy and safety of platelet rich plasma in reducing scalp symptoms and promoting hair growth in patients diagnosed with frontal fibrosing alopecia. Platelet rich plasma is an autologous blood product, and platelet rich plasma will be administered intralesionally for this study. The platelet rich plasma used for this study will be prepared using the Eclipse Easy Spin centrifuge.

Description:

The primary objective of this study is to assess the efficacy and safety of platelet rich plasma in reducing scalp symptoms and promoting hair growth in patients diagnosed with frontal fibrosing alopecia. The secondary objective of this study is subject self-assessment through the Dermatology Quality Life Index (DQLI) and Hair-Growth Assessment (HGA) as well as investigator-assessment from baseline. Platelet rich plasma is an autologous blood product, and platelet rich plasma will be administered intralesionally for this study. The platelet rich plasma used for this study will be prepared using the Eclipse Easy Spin centrifuge. The duration of this study for participants is 8 months, including an initial screening visit, 6 monthly treatment visits, and a follow-up visit. Subjects eligible for this study are those diagnosed with frontal-fibrosing alopecia via biopsy and clinical assessment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: September 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females, ages 18 and older

• Diagnosed by a board-certified dermatologist with frontal fibrosing alopecia

• Scalp biopsy consistent with frontal fibrosing alopecia diagnosis

• Willing to use Head and Shoulders shampoo for the scalp while in study

• Willing to abstain from over the counter and prescription hair/scalp products other than those supplied in the study

• Willing to abstain from the use of non-steroidal anti-inflammatory medications, aspirin, St, John's Wart, and high doses of Vitamin E supplementation for 4 weeks

• Subjects must be capable of giving informed consent

• Stated willingness to comply with all study procedures and be available for the duration of the study

• For women with reproductive potential, a willingness to use methods of contraception that will prevent the subject from becoming pregnant during the study. Adequate contraception methods include hormonal methods used for two or more menstrual cycles before screening (eg. oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), barrier methods (eg, contraceptive sponge, diaphragm in conjunction with contraceptive foam or jelly, or condom in conjunction with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (eg, tubal ligation or a monogamous relationship with a vasectomized partner) and abstinence

Exclusion Criteria:

• Current immunosuppression

• Oral treatment of FFA within the last 3 months (such as hydroxycholroquine, doxycycline, minocycline, acitretin, mycophenolate mofetil, cyclosporine, prednisone, rituximab, and pioglitazone etc.)

• History of other scalp/hair disease

• Current chemotherapy or radiation

• Propensity for keloids or hypertrophic scarring

• Autoimmune disorders

• Hematologic disorder or bleeding disorder

• Platelet dysfunction

• Use of anticoagulation therapy

• Active malignancy

• Use of intralesional or topical corticosteroids in the last 6 weeks

• Scalp atrophy

• Pregnant and/or breastfeeding

• Allergy or intolerance to triamcinolone

• Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies

• Medical problems including HIV, connective tissue disorder, PCOS, or untreated thyroid disease

• Any psychiatric or medical condition that in the opinion of the investigator will interfere with patient's ability to participate in the trial

• Current use of tanning beds or any active tanning

• Planned upcoming pregnancy

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Frontal Fibrosing Alopecia

Intervention

Device:
• Eclipse Easy Spin for PRP
Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.

Locations

Country	Name	City	State
United States	University of Minnesota Department of Dermatology	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the LPPAI score from baseline	Changes in LPPAI (LICHEN PLANOPILARIS ACTIVITY INDEX) Scale of of 0-4 0= None 4=Severe	Baseline to 3 years
Primary	Changes in the hair growth from baseline to the completion of the study • Change in hair growth from baseline to study completion via investigator assessment of scalp photography	Changes in hair growth from baseline to study completion using scalp photography hair growth in patients diagnosed with frontal fibrosing alopecia	Baseline to 3 years
Secondary	self-assessment using the Dermatology Quality Life Index	Subject self-assessment using the Dermatology Quality Life Index (DQLI)	Baseline to 3 years